AstraZeneca Says Cancer Drug Lynparza Shows Overall Survival in Prostate Cancer
April 24 2020 - 2:50AM
Dow Jones News
By Anthony O. Goriainoff
AstraZeneca PLC said Friday that its cancer drug Lynparza showed
an overall survival in men with metastatic castration-resistant
prostate cancer during a Phase 3 PROfound trial.
The pharmaceutical giant said the drug showed significant
clinical benefit across key endpoints in PROfound testing,
including overall survival for male patients with breast cancer
genes or ATM mutations, and that the drug's safety and tolerability
profile was generally compatible with previous trials.
Write to Anthony O. Goriainoff at
anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
April 24, 2020 02:35 ET (06:35 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Aug 2024 to Sep 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Sep 2023 to Sep 2024